Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CD | O00329 | 14/20 | 0.52 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.50 |
| ▸ | GPR119 | Q8TDV5 | 3/20 | 0.47 |
| ▸ | CHEK2 | O96017 | 1/20 | 0.47 |
| ▸ | PIK3CA | P42336 | 2/20 | 0.47 |
| ▸ | PIK3CB | P42338 | 2/20 | 0.47 |
| ▸ | PIK3CG | P48736 | 2/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21603185 | 1.00 | PIK3CD (0.52) | PIK3CDUSP30GPR119CHEK2PIK3CA | |
| SCHEMBL21603197 | 1.00 | PIK3CD (0.52) | PIK3CDUSP30GPR119CHEK2PIK3CA | |
| SCHEMBL20281619 | 0.93 | CHEK2 (0.55) | PIK3CDUSP30GPR119CHEK2 | |
| SCHEMBL20281604 | 0.93 | CHEK2 (0.55) | PIK3CDUSP30GPR119CHEK2 | |
| SCHEMBL21604523 | 0.93 | CHEK2 (0.55) | PIK3CDUSP30GPR119CHEK2 | |
| SCHEMBL21606918 | 0.92 | GPR119 (0.55) | GPR119CHEK2 | |
| SCHEMBL23791590 | 0.91 | PIK3CD (0.49) | PIK3CDUSP30GPR119CHEK2PIK3CA | |
| SCHEMBL21603200 | 0.91 | PIK3CD (0.49) | PIK3CDUSP30GPR119CHEK2PIK3CA | |
| SCHEMBL23791463 | 0.86 | PIK3CD (0.51) | PIK3CDUSP30GPR119PIK3CAPIK3CB | |
| SCHEMBL21606915 | 0.85 | GPR119 (0.46) | PIK3CDUSP30GPR119 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210277015-A1 | OGA INHIBITOR COMPOUNDS | JANSSEN-CILAG S.A. (ES) | 2021-09-09 | — | — | US | disclosed |
| WO-2019243527-A1 | OGA INHIBITOR COMPOUNDS | JANSSEN PHARMACEUTICA NV (BE) | 2019-12-26 | — | — | WO | disclosed |
| WO-2019243531-A1 | OGA INHIBITOR COMPOUNDS | JANSSEN PHARMACEUTICA NV (BE) | 2019-12-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210277015-A1 | OGA INHIBITOR COMPOUNDS | OGA, OGT, GRN | PIK3CD 1988/4885USP30 403/4885GPR119 1166/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.